110.87
price up icon0.18%   0.20
after-market アフターアワーズ: 111.00 0.13 +0.12%
loading
前日終値:
$110.67
開ける:
$110.61
24時間の取引高:
6.60M
Relative Volume:
0.74
時価総額:
$136.94B
収益:
$28.73B
当期純損益:
$5.97B
株価収益率:
23.34
EPS:
4.75
ネットキャッシュフロー:
$9.84B
1週間 パフォーマンス:
+4.41%
1か月 パフォーマンス:
+0.72%
6か月 パフォーマンス:
+20.50%
1年 パフォーマンス:
+61.59%
1日の値動き範囲:
Value
$109.88
$111.44
1週間の範囲:
Value
$104.46
$112.00
52週間の値動き範囲:
Value
$66.01
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
名前
Gilead Sciences Inc
Name
セクター
Healthcare (1173)
Name
電話
(650) 574-3000
Name
住所
333 LAKESIDE DR, FOSTER CITY, CA
Name
職員
17,600
Name
Twitter
@GileadSciences
Name
次回の収益日
2025-02-11
Name
最新のSEC提出書
Name
GILD's Discussions on Twitter

GILD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
110.87 136.94B 28.73B 5.97B 9.84B 4.75
Drug Manufacturers - General icon
LLY
Lilly Eli Co
779.53 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
152.75 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
69.02 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.62 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
121.01 234.21B 53.22B 12.86B 14.85B 6.39

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-22 再開されました Cantor Fitzgerald Overweight
2025-03-04 繰り返されました Oppenheimer Outperform
2025-02-18 アップグレード Deutsche Bank Hold → Buy
2025-02-13 アップグレード DZ Bank Hold → Buy
2025-01-10 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-12-10 再開されました BofA Securities Buy
2024-11-15 開始されました Wolfe Research Outperform
2024-11-14 開始されました Citigroup Buy
2024-11-08 ダウングレード Maxim Group Buy → Hold
2024-10-21 アップグレード Leerink Partners Market Perform → Outperform
2024-10-17 開始されました Bernstein Outperform
2024-10-07 アップグレード Wells Fargo Equal Weight → Overweight
2024-07-08 アップグレード Raymond James Mkt Perform → Outperform
2024-05-01 繰り返されました Maxim Group Buy
2024-04-24 アップグレード HSBC Securities Reduce → Hold
2024-02-22 ダウングレード Truist Buy → Hold
2023-11-09 開始されました Deutsche Bank Hold
2023-09-08 アップグレード BofA Securities Neutral → Buy
2023-09-06 開始されました HSBC Securities Reduce
2023-07-24 繰り返されました Barclays Equal Weight
2023-05-16 アップグレード BMO Capital Markets Market Perform → Outperform
2023-04-28 再開されました Piper Sandler Overweight
2023-01-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2022-12-13 再開されました BofA Securities Neutral
2022-12-09 ダウングレード DZ Bank Buy → Hold
2022-10-31 アップグレード Barclays Underweight → Equal Weight
2022-10-28 繰り返されました BMO Capital Markets Market Perform
2022-10-28 繰り返されました Cowen Outperform
2022-10-28 繰り返されました JP Morgan Overweight
2022-10-28 繰り返されました Jefferies Buy
2022-10-28 アップグレード Piper Sandler Neutral → Overweight
2022-10-28 繰り返されました RBC Capital Mkts Outperform
2022-10-28 アップグレード Truist Hold → Buy
2022-10-28 繰り返されました Wells Fargo Equal Weight
2022-10-04 アップグレード JP Morgan Neutral → Overweight
2022-07-13 開始されました Cantor Fitzgerald Neutral
2022-05-23 開始されました SVB Leerink Mkt Perform
2022-02-28 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-02-02 繰り返されました BMO Capital Markets Outperform
2022-02-02 繰り返されました BofA Securities Neutral
2022-02-02 繰り返されました RBC Capital Mkts Outperform
2022-02-02 繰り返されました Truist Hold
2022-02-02 繰り返されました Wells Fargo Equal Weight
2022-01-28 アップグレード Argus Hold → Buy
2022-01-06 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-12-09 再開されました Wells Fargo Equal Weight
2021-12-06 開始されました Goldman Neutral
2021-11-19 アップグレード BMO Capital Markets Market Perform → Outperform
2021-11-19 再開されました Piper Sandler Neutral
2021-10-20 再開されました Cowen Outperform
2021-07-30 繰り返されました BMO Capital Markets Market Perform
2021-07-30 繰り返されました RBC Capital Mkts Outperform
2021-04-01 アップグレード Bernstein Mkt Perform → Outperform
2021-03-30 アップグレード Redburn Neutral → Buy
2021-01-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-01-04 アップグレード Guggenheim Neutral → Buy
2020-11-03 再開されました Morgan Stanley Equal-Weight
2020-10-28 開始されました UBS Neutral
2020-09-30 再開されました Jefferies Buy
2020-09-15 アップグレード Maxim Group Hold → Buy
2020-07-31 繰り返されました Credit Suisse Neutral
2020-07-31 繰り返されました Morgan Stanley Equal-Weight
2020-07-31 繰り返されました Piper Sandler Overweight
2020-07-31 繰り返されました RBC Capital Mkts Outperform
2020-07-31 繰り返されました SunTrust Hold
2020-07-31 繰り返されました Wells Fargo Equal Weight
2020-07-20 アップグレード Credit Suisse Underperform → Neutral
2020-06-03 アップグレード SVB Leerink Mkt Perform → Outperform
2020-05-26 アップグレード SunTrust Sell → Hold
2020-05-01 ダウングレード JP Morgan Overweight → Neutral
2020-05-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-01 ダウングレード SunTrust Hold → Sell
2020-04-27 ダウングレード UBS Buy → Neutral
2020-04-20 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-04-20 ダウングレード Wells Fargo Overweight → Equal Weight
2020-04-17 ダウングレード CFRA Hold → Sell
すべてを表示

Gilead Sciences Inc (GILD) 最新ニュース

pulisher
Jun 19, 2025

Gilead Sciences Lands First FDA Approval of a Twice-a-Year HIV PrEP Drug - MedCity News

Jun 19, 2025
pulisher
Jun 18, 2025

US FDA approves Gilead's twice-yearly injection for HIV prevention - Deccan Herald

Jun 18, 2025
pulisher
Jun 18, 2025

US approves Gilead’s twice-yearly injection to prevent HIV - The Malaysian Reserve

Jun 18, 2025
pulisher
Jun 18, 2025

US approves Gilead's twice-yearly injection to prevent HIV - El Paso Inc.

Jun 18, 2025
pulisher
Jun 18, 2025

The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it - Shelton Herald

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences facility video - KTIV

Jun 18, 2025
pulisher
Jun 18, 2025

HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS News

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves Gilead's twice-yearly HIV prevention shot - FirstWord Pharma

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Wins Historic Approval for Twice-Yearly HIV Drug - BioSpace

Jun 18, 2025
pulisher
Jun 18, 2025

HIV advance: Twice-yearly shot to prevent infection - NZ Herald

Jun 18, 2025
pulisher
Jun 18, 2025

Cautious Optimism for Gilead Sciences Amid Yeztugo’s Market Challenges - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's twice-yearly PrEP drug is cleared by FDA - pharmaphorum

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves twice-yearly shot of Gilead drug for HIV prevention - BioPharma Dive

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It? - Investor's Business Daily

Jun 18, 2025
pulisher
Jun 18, 2025

US Approves Gilead's Twice-yearly Injection To Prevent HIV - Barron's

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Gilead’s Twice-Yearly Injection for HIV Prevention - The Well News

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves 6-month HIV prevention shot - The Hill

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's (GILD) HIV Treatment Yeztugo Gains FDA Approval, Market Potential Expands | GILD Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approval Boosts Gilead's (GILD) Prospects in HIV Prevention | GILD Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences stock steady as FDA approves twice-yearly HIV prevention - Investing.com UK

Jun 18, 2025
pulisher
Jun 18, 2025

Mizuho says Gilead Yeztugo label looks clean - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences (GILD) Gains FDA Nod for HIV Prevention Drug - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time. - Barron's

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences’ Yeztugo Approval and Market Expansion Drive Buy Rating - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves powerful HIV prevention drug: What to know about Yeztugo - NBC News

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves the world’s only twice-a-year shot to prevent HIV - mypanhandle.com

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention - ContagionLive

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead’s twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead - Proactive financial news

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences' HIV Prevention Drug Yeztugo Receives FDA Approval - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead (GILD) Gains FDA Approval for Unique HIV Prevention Drug Yeztugo | GILD Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead’s Twice-a-Year HIV Prevention Shot Wins US FDA Approval - Bloomberg.com

Jun 18, 2025
pulisher
Jun 18, 2025

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection - marketscreener.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's (GILD) Lenacapavir Advances as HIV Prevention Treatment - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead (GILD) Gains FDA Approval for HIV Prevention Injection | - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead’s twice-yearly HIV prevention shot gets FDA approval - Investing.com Australia

Jun 18, 2025
pulisher
Jun 18, 2025

US FDA approves Gilead’s twice-yearly injection for HIV prevention By Reuters - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead’s twice-yearly HIV prevention shot gets FDA approval By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead stock gains on FDA nod for HIV PrEP drug (GILD:NASDAQ) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option - CNBC

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access? - STAT

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention - marketscreener.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award - CSRwire

Jun 18, 2025
pulisher
Jun 18, 2025

Buy, Sell, Or Hold GILD Stock? - Trefis

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jun 18, 2025
pulisher
Jun 18, 2025

Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's HIV drug could end epidemic, but the company has a dark side - Fast Company

Jun 18, 2025
pulisher
Jun 17, 2025

Insider Sell: Andrew Dickinson Sells 2,500 Shares of Gilead Sciences Inc (GILD) - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: ReportGilead Sciences (NASDAQ:GILD) - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern - Insider Monkey

Jun 17, 2025
pulisher
Jun 16, 2025

Levi & Korsinsky Investigates Gilead Sciences, Inc. (GILD) Over Possible Securities Fraud - ACCESS Newswire

Jun 16, 2025

Gilead Sciences Inc (GILD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Gilead Sciences Inc (GILD) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Mercier Johanna
Chief Commercial Officer
Jun 16 '25
Sale
110.17
3,000
330,510
120,168
drug_manufacturers_general PFE
$24.24
price up icon 0.21%
drug_manufacturers_general SNY
$48.31
price up icon 0.96%
$279.21
price up icon 0.75%
drug_manufacturers_general MRK
$79.16
price up icon 0.08%
drug_manufacturers_general NVS
$121.01
price up icon 0.83%
大文字化:     |  ボリューム (24 時間):